Category Archives: Carolyn Baglole

View her faculty profile here: Carolyn Baglole, PhD
Associate Professor, Department of Medicine, McGill Universiy
Research Theme: Cellular and molecular signalling pathways which regulate chronic lung disease caused by cigarette smoke
Keywords: chronic obstructive pulmonary disease • toxicology • cigarette smoke • inflammation • lungs • cannabis
View Carolyn Baglole’s recent posts and news below.

CCIC Researcher Profile – Dr. Carolyn Baglole

Dr. Carolyn Baglole was featured in the July 2019 CCIC Newsletter. Her research was profiled in their monthly research highlights. Read the newsletter excerpt below.

Dr. Baglole received her BSc and MSc from the University of Prince Edward Island, and completed her PhD at the University of Calgary. She then did postdoctoral work in the fields of lung biology/toxicology in the Department of Environment Medicine at the University of Rochester (Rochester NY) before returning to Canada at McGill University.

Dr. Baglole’s translational research program seeks to identify novel cellular and molecular pathways that regulate the pathogenesis of chronic lung diseases. Her main research focus is to understand how these environmental exposures contribute to pathogenic mechanisms such as chronic inflammation and cell death (apoptosis) that drive the development of diseases such as chronic obstructive pulmonary disease (COPD) and lung cancer.

In relation to the CCIC, her lab is currently examining how various forms of inhaled cannabis and/or cannabinoids affects lung and immune function. Using pre-clinical models, her team will investigate activation of cellular signaling pathways by exposure to cannabis/cannabinoids, how cannabis exposure effects immune cell numbers and function and whether newer forms of inhaled cannabis products impact lung function. Working with clinicians and other scientists, she is developing an interdisciplinary program for biomedical cannabis research to explore the full potential of cannabis and cannabinoids in human health and disease. For this, she will have a state-of-the-art inhalation facility. This is important, as the most common way to consume cannabis is through inhalation (of smoke or vaporized cannabis/cannabinoids). With this, she will be able to deliver inhaled cannabis and cannabis-derived cannabinoids/novel drugs in a real-world scenario to assess efficacy in disease models and understand the immune-medicated mechanisms involved in the potential therapeutic benefits of cannabis.

Read more about Dr. Baglole: https://www.meakinsmcgill.com/baglole/

Read more about the McGill Research Centre for Cannabis: https://mcgill.ca/cannabis/



Human Airway Branch Variation and Chronic Obstructive Pulmonary Disease

Airway Branching Associated with COPD Risk

Dr. Benjamin Smith, in collaboration with Dr. Carolyn Baglole and Columbia University Irving Medical Center, published “Human Airway Branch Variation and Chronic Obstructive Pulmonary Disease” in the Proceedings of the National Academy of Sciences. Together, their study shows that the internal anatomy of our lungs is surprisingly variable. Furthermore, some of those variations are associated with a greater risk of chronic obstructive pulmonary disease (COPD). (January 2018)

View full publication: Human airway branch variation and chronic obstructive pulmonary disease. Smith BM, Traboulsi H, Austin JHM, Manichaikul A, Hoffman EA, Bleecker ER, Cardoso WV, Cooper C, Couper DJ, Dashnaw SM, Guo J, Han MK, Hansel NN, Hughes EW, Jacobs DR Jr, Kanner RE, Kaufman JD, Kleerup E, Lin CL, Liu K, Lo Cascio CM, Martinez FJ, Nguyen JN, Prince MR, Rennard S, Rich SS, Simon L, Sun Y, Watson KE, Woodruff PG, Baglole CJ, Barr RG; MESA Lung and SPIROMICS investigators. Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):E974-E981. doi: 10.1073/pnas.1715564115. Epub 2018 Jan 16. PMID: 29339516

View articles and interviews about this research:

funding news for the Meakins-Christie Laboratories

Prognostic and therapeutic utility of human antigen R (HUR) in idiopathic pulmonary fibrosis

Dr. Carolyn Baglole was interviewed about her recent grant entitled “Prognostic and therapeutic utility of human antigen R (HUR) in idiopathic pulmonary fibrosis”. Her project received 2 year funding from Boehringer-Ingleheim’s Innovation in Understanding ILD (BUILD) program. (April 2017)

Read more here: BUILD grant breathes life into lung disease research. Supported by funding from Boehringer Ingelheim (Canada) Ltd, Carolyn Baglole hopes to unravel the mystery of idiopathic pulmonary fibrosis, a fatal lung disease that affects some 15,000 Canadians.